FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026, Updated July 22, 2026: The week of July 20 decides more about compounded weight-loss access than the previous six months did, and the second decision in it has barely been reported as a compounding story at all. On April 30, 2026, the FDA published a proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use in compounding, regardless of drug shortage status. Public comment on the proposal closed July 30, 2026 (extended from June 29 via Federal Register 2026-12937, published June 26, 2026). If finalized, no 503B pharmacy could legally bulk-compound any of these three GLP-1 drugs in the future, even if a new shortage is declared. This is a permanent structural change, not a temporary shortage-enforcement action.

• •What changed: FDA proposed permanent 503B exclusion for semaglutide, tirzepatide, and liraglutide on April 30, 2026
• •Comment period: Closed July 30, 2026, extended from June 29 via Federal Register 2026-12937 (91 FR 38719, published June 26, 2026) under Docket FDA-2018-N-3240. Comments are no longer accepted; the notice remains readable at the Federal Register notice (the page has a 'Submit a Formal Comment' button that routes to the active regulations.gov docket).
• •Immediate patient impact: None, the proposal is not yet finalized. Current shortage-based bans remain in place unchanged.
• •If finalized: 503B outsourcing facilities permanently cannot bulk-compound these three drugs, even during a future shortage
• •What stays legal: 503A patient-specific compounding under narrow medical-necessity criteria (allergy to inactive ingredients, non-standard dose)
• •Compounded tirzepatide: Still legal now, tirzepatide shortage is active. Monitor FDA alerts for changes.

What the 503B Bulk List Is, and Why This Matters

503B outsourcing facilities are large-scale pharmaceutical manufacturers licensed by the FDA to compound drugs at commercial scale. Unlike 503A patient-specific pharmacies, which fill individual prescriptions one at a time, 503B facilities can produce bulk quantities for healthcare facilities and telehealth platforms. That production capacity is what powered the compounded GLP-1 boom from 2021 to 2025.

Under federal law, 503B facilities can compound drugs using ingredients from the FDA's 'nominated bulk drugs' list. The list exists to allow compounding when brand-name supply is short. When a drug is removed from the shortage list, compounders lose their legal basis to produce it at scale, but under the current rules, they could theoretically restart if a new shortage is declared. The permanent exclusion proposal closes that door permanently.

The FDA's stated rationale, per the Orrick regulatory analysis of the proposal: when manufacturers have proven they can maintain adequate supply, allowing large-scale 503B compounding of their products creates safety risks without the shortage benefit. Over 520 adverse event reports linked to compounded GLP-1 products, including contamination, dosing errors, and unapproved additives, are part of the agency's record supporting permanent exclusion.

How This Differs from the Current Semaglutide and Tirzepatide Enforcement

The current semaglutide crackdown and compounded tirzepatide rules are both shortage-dependent: they are enforced because FDA removed semaglutide from the shortage list in October 2024 and because tirzepatide remains on the shortage list, respectively. The new proposal operates on entirely different legal authority.

In practical terms: the current enforcement says 'you cannot compound semaglutide because the shortage is over.' The proposed permanent ban says 'even if semaglutide goes back on shortage in the future, 503B facilities still cannot bulk-compound it.' That removes any path back to the pre-2025 compounded GLP-1 market for large-scale outsourcing facilities.

Why Liraglutide Is Included in the Proposal

Liraglutide, the active ingredient in Victoza (type 2 diabetes) and Saxenda (weight loss), is an older GLP-1 with no active shortage. Including it in the permanent exclusion proposal signals the FDA is closing a potential substitution loophole: as semaglutide and tirzepatide compounding access narrows, some 503B facilities could shift production to liraglutide, which shares GLP-1 mechanisms and is technically similar to compound at scale.

Liraglutide produces 5-6% body weight loss versus 15-21% for tirzepatide and 15% for semaglutide, so it was not the primary driver of the compounded GLP-1 market. But the FDA is not leaving that gap open. Including liraglutide now prevents a second enforcement cycle later.

What Remains Legal: Your 503A Patient-Specific Options

The permanent exclusion proposal applies exclusively to 503B outsourcing facilities. It does not change the rules for 503A patient-specific compounding pharmacies, which operate under a different section of the Federal Food, Drug, and Cosmetic Act. Under 503A, a licensed prescriber can still write a patient-specific prescription for compounded semaglutide, tirzepatide, or liraglutide if:

• •Documented allergy, The patient has a verified allergy to a specific inactive ingredient in the commercial product that is not present in the compounded formulation
• •Non-commercially-available dose, The patient requires a specific dose or concentration that is not available in any FDA-approved strength
• •Individual prescription required, The prescriber must document medical necessity for each individual patient; standing orders for patient populations do not qualify

The July 23-24 PCAC Peptide Vote: What the Committee Actually Recommended

There was a second compounding decision in the same window as the 503B comment deadline, and it has been almost entirely covered as a peptide story rather than a compounding story. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at the White Oak campus to review seven peptides nominated for the 503A bulks list, the list that governs patient-specific compounding. This is the same regulatory machinery that decided the GLP-1 question, applied to the substances the peptide market moved into after the semaglutide and tirzepatide crackdowns.

The agenda splits across two days, and the Federal Register meeting notice names both the substances and the specific uses the FDA evaluated for each one. That second column matters more than the peptide names: the committee is not asked whether a peptide is interesting, it is asked whether there is a clinical need for compounding it for a stated use.

Note the one that overlaps our territory directly: MOTs-C was evaluated for obesity and osteoporosis. If you have been offered a peptide as a cheaper alternative to a GLP-1, this is the meeting that decides whether a compounding pharmacy can legally keep sourcing bulk material for it.

The market traded both days hard, which is worth knowing only because it tells you how much money is watching this list. Hims and Hers rose more than 10% intraday on July 23 after the BPC-157 vote landed, then gave most of it back to close up around 3% at $32.74. When emideltide became the first substance the panel turned down on July 24, the stock fell about 11%. Share prices are not evidence about a peptide, and they play no part in how we score or rank any provider. Vote tallies via STAT and the FDA advisory committee meeting page.

For your purposes as someone comparing weight-loss options, nothing legally changed on July 23. MOTs-C got a favorable committee recommendation for obesity, but a recommendation is not approval, the FDA has not acted, and the safety record below is exactly why the agency's own scientists advised against it. The proven, FDA-regulated weight-loss options are still the ones in our full provider rankings and our cheapest GLP-1 comparison. If you are researching these peptides in their own right rather than as a GLP-1 alternative, our sister site Best Peptide For That covers the vote and each peptide's evidence in depth.

Why the FDA Is Skeptical of Bulk Peptides: The Safety Record

The strongest argument against adding these peptides to the 503A list is not about the molecules. It is about what is actually in the vial. The supply chain feeding US compounders runs largely through foreign API manufacturers, and the FDA's own enforcement record from this year is unflattering.

• •A named manufacturer, in writing. On April 15, 2026 the FDA issued a warning letter to Hangzhou Yiqi Biotechnology, a registered API manufacturer in Zhejiang, China. The letter cites failure to perform process validation, failure to validate analytical test methods, and failure to run a stability program. Its blunt conclusion: the firm's APIs are 'adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act.'
• •Already blocked at the border. The same letter records that the FDA 'placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026,' three months before the warning letter itself was published. Enforcement here runs ahead of the paperwork the public can see.
• •Testing failure rates are not a rounding error. The Partnership for Safe Medicines, summarizing reporting on the bulk peptide market, cites a Texas testing lab finding that a third of peptide samples fail identity, purity, or quantity checks, and points to FDA adverse-event records including a life-threatening incident and a hospitalization linked to suspected contamination in BPC-157.

How to Submit a Public Comment Before July 30

The public comment period on the proposal closed July 30, 2026 (Docket FDA-2018-N-3240; extended from June 29 via Federal Register 2026-12937, 91 FR 38719, published June 26, 2026). Patients, prescribers, pharmacists, telehealth companies, and patient advocacy organizations were able to submit comments up to that date. The FDA reviews all substantive comments before issuing a final rule, and no final rule had been announced as of August 3, 2026.

• •Where to comment: the Federal Register notice 2026-08552, use the 'Submit a Formal Comment' button on that page, which routes to the active regulations.gov docket
• •What carries weight: Documented patient cases, clinical data, safety comparisons between 503B products and brand-name drugs, economic impact for patients who relied on compounded access
• •Who should comment: Patient advocacy groups, healthcare providers who prescribe compounded GLP-1s, pharmacy associations, and patients using legitimate medical-necessity exemptions
• •Deadline: July 30, 2026, extended from June 29, 2026 via Federal Register 2026-12937. Comments submitted after this date will not be considered in the final rule.

What This Means for Your GLP-1 Access Right Now

The proposal is not yet finalized. The comment period closed July 30, 2026 (Docket FDA-2018-N-3240; extended from June 29 via FR 2026-12937) and the proposal is now with the FDA for review, so a final rule could come at any point and none had been announced as of August 3, 2026. Your immediate access is governed by the current rules, not the proposed permanent ban. Here is where things stand by drug:

If you are currently on compounded tirzepatide from a licensed 503B provider, you have time. The tirzepatide shortage remains active as of May 2026. But the direction of travel is clear: FDA is systematically closing large-scale GLP-1 compounding. Our featured compliant compounded tirzepatide picks, Enhance MD (from $99 first month), Shed ($299/mo), and Yucca Health ($258/mo, 6-month plan), all operate under verified pharmacy partnerships.

If you need to switch off compounded semaglutide, your best current paths are brand-name Wegovy ($349/mo via NovoCare), Zepbound from telehealth providers like Sprout Health ($199 first month, then $249/mo), or the newly approved oral option Foundayo (orforglipron) from $149/mo, or see all FDA-approved oral GLP-1 pills compared. For the complete switch guide, see compounded semaglutide: 4 legal alternatives.

Frequently Asked Questions

Does this proposal affect my current compounded tirzepatide prescription? Possibly, over time. Tirzepatide came off the FDA shortage list in late 2024, and shortage-based compounding enforcement began in early 2025, so compounded tirzepatide today is made under narrow 503A patient-specific medical-necessity rules. This proposal targets the separate 503B bulk route and is not yet finalized, so it does not change a valid 503A prescription immediately, but if finalized it would further tighten large-scale supply. Check our FDA safety alerts for real-time status.

Can my doctor still prescribe compounded semaglutide under 503A? Yes, under narrow medical-necessity criteria, documented allergy to inactive ingredients, or a required dose not available commercially. The 503B permanent exclusion proposal does not change 503A patient-specific rules.

Is there any scenario where 503B compounding of semaglutide could restart under the current rules? Yes, technically, if semaglutide went back on the FDA shortage list. That is exactly the loophole the permanent exclusion proposal is designed to close. If finalized, no future shortage declaration would reopen 503B compounding for these three drugs.

Why is liraglutide in the proposal if almost no one is using it for weight loss? The FDA is preventing a substitution market from forming. As semaglutide and tirzepatide 503B access closes, facilities could pivot to liraglutide compounding. Including it now avoids a second enforcement cycle.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical or legal advice. GLP-1 medications require a prescription from a licensed healthcare provider. Consult your prescriber before making any changes to your medication regimen. Regulatory status reflects information available as of May 8, 2026 and is subject to change.

Sources